Real-world series on alloHCT for PTCL: adverse factors for PFS
| . | CIBMTR/EBMT LY19-0124; EBMT (data on file) . | JSTCT21 . | GETH/GELTAMO30 . | SFGM-TC25 . | DSHNHL18 . | CIBMTR AITL26 . |
|---|---|---|---|---|---|---|
| N . | 1942 . | 312 . | 201 . | 285 . | 84 . | 249 . |
| Patient related | ||||||
| Age (higher) | ++ | ++ | — | NA | - | - |
| PS (poorer) | ++ | ++ | ++ | NA | ++ | - |
| Disease related | ||||||
| Non-AITL | ++ | - | NA | - | NA | NA |
| Prior autoHCT | — | NA | NA | NA | - | - |
| Second line (vs first-line) | - | NA | - | NA | NA | |
| Refractory @ alloHCT | ++ | ++ | — | + | + | ++ |
| Transplant related | ||||||
| Cell source BM | — | — | — | NA | NA | NA |
| Donor unrelated | — | NA | NA | NA | - | - |
| Donor haplo | — | NA | NA | NA | NA | NA |
| Conditioning MAC | — | — | + | - | NA | - |
| Conditioning RIC | — | — | — | - | NA | - |
| . | CIBMTR/EBMT LY19-0124; EBMT (data on file) . | JSTCT21 . | GETH/GELTAMO30 . | SFGM-TC25 . | DSHNHL18 . | CIBMTR AITL26 . |
|---|---|---|---|---|---|---|
| N . | 1942 . | 312 . | 201 . | 285 . | 84 . | 249 . |
| Patient related | ||||||
| Age (higher) | ++ | ++ | — | NA | - | - |
| PS (poorer) | ++ | ++ | ++ | NA | ++ | - |
| Disease related | ||||||
| Non-AITL | ++ | - | NA | - | NA | NA |
| Prior autoHCT | — | NA | NA | NA | - | - |
| Second line (vs first-line) | - | NA | - | NA | NA | |
| Refractory @ alloHCT | ++ | ++ | — | + | + | ++ |
| Transplant related | ||||||
| Cell source BM | — | — | — | NA | NA | NA |
| Donor unrelated | — | NA | NA | NA | - | - |
| Donor haplo | — | NA | NA | NA | NA | NA |
| Conditioning MAC | — | — | + | - | NA | - |
| Conditioning RIC | — | — | — | - | NA | - |
++ or - -, multivariate analysis; + or -, univariate analysis.
BM, bone marrow; MAC, myeloablative conditioning; NA, not available; RIC, reduced-intensity conditioning.